The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha ® (evolocumab) Injection, the first proprotein ...

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...

To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...

The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...

The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as an adjunct to diet: in combination with a statin or statin with ...

Repatha is the second in a new class of drugs called PCSK9 inhibitors to win FDA approval The drug is a second line of treatment for those who can't take or don't respond to widely used statins for ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...